Prevalence and clinical outcome of Philadelphia-like acute lymphoblastic leukemia: A systematic review and meta-analysis

Publication date: Available online 27 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Weerapat Owattanapanich, Pongprueth Rujirachun, Patompong Ungprasert, Jassada Buaboonnam, Piti TechavichitAbstractBackgroundThe presence of Philadelphia (Ph)-like ALL among patients with acute lymphoblastic leukemia (ALL) may indicate a poor prognosis similar to Philadelphia positive (Ph+) ALL although the data are still inconclusive and the prevalence of Ph-like ALL varied considerably across the studies.MethodsThe current systematic review and meta-analysis were conducted with the aims to identify all cohort studies of patients with ALL that reported the prevalence of Ph-like ALL and summarize their results together. The pooled prevalence and rate were calculated using DerSimonian-Laird random-effect model with double arcsine transformation.ResultsAcross the 15 included studies which consisted of 11,040 ALL patients, the peak prevalence of the presence Ph-like ALL among patients with ALL was between ages 11-40 years where the pooled prevalence was 25.8-26.2%. The pooled 5-year overall survival (OS) rate of Ph-like ALL was 42.8% (95% CI, 23.9%–64.1%; I2 93%). Comparative analysis with B-other ALL patients was conducted using Mantel-Haenszel method and found that Ph-like ALL patients had a significantly lower chance of surviving at 5-year with the pooled odds ratio (OR) 0.35 (95% CI 0.25-0.50, p
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsFLT3 mutation was not common in Chinese ALL patients. Age of onset, platelet counts and transplant status rather than FLT3 mutations were independent prognostic variables for ALL cases on OS in our cohort. In spite of small sample size, ETP-ALL may indicate a comparable higher FLT3-mutant rate. Since ETP-ALL has been identified as high-risk subgroup, these data warrant clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic hematopoietic stem cell transplantation for FLT3 mutant ETP-ALL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 30 September 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Guillaume Richard-Carpentier, Elias Jabbour, Nicholas J. Short, Caitlin R. Rausch, Jonathan M. Savoy, Prithviraj Bose, Musa Yilmaz, Nitin Jain, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Michael Rytting, Partow Kebriaei, Marina Konopleva, Hagop Kantarjian, Farhad RavandiAbstractBackgroundPatients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) have dismal outcomes. Preclinical studies suggest that T-ALL cells are sensitive to BCL2 inhibition. Clinical activity of venetocla...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Activating mutations in FLT3 are frequent in acute myeloid leukemia (AML) and have important prognostic and therapeutic implications. Meanwhile, FLT3 aberrations have been detected in a smaller fraction of acute lymphoblastic leukemia (ALL), and their prognostic value are not well established. Therefore, we assessed the FLT3 mutation in Chinese adolescent and adult ALL patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Combination therapies including venetoclax were administered to 13 patients with relapsed/refractory T-ALL at our institution. Marrow responses were achieved in 60% of evaluable patients and 2 patients with early T-cell precursor (ETP) ALL remain alive in remission. Venetoclax combination therapies are safe and myelosuppression was the main adverse event observed with the addition of this drug.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin’s lymphoma or non-Hodgkin’s lymphoma (HL/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL/LL). Analyses were censored at HM o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackground/AimThe optimal the conditioning regimens for allogeneic hematopoietic stem cell transplantation (HSCT), especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4,255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1,562 myeloablative conditioning (MAC) and 2,693 non-myeloablative conditi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The presence of Philadelphia (Ph)-like ALL among patients with acute lymphoblastic leukemia (ALL) may indicate a poor prognosis similar to Philadelphia positive (Ph+) ALL although the data are still inconclusive and the prevalence of Ph-like ALL varied considerably across the studies.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Auer rods were first described in the cytoplasm of leukemia blasts by John Auer in 1906. Auer rods are commonly seen in myeloid progenitors, and serve as a diagnostic morphological feature of acute myeloid leukemia (AML) [1]. The differential diagnosis of hematopoietic neoplasms relies on the detection of cytoplasmic inclusions resembling Auer rods. Auer rod-like inclusions have been described in multiple myeloma [2], prolymphocytic leukemia (PLL) [3], B-cell acute lymphoblastic leukemia [4], chronic lymphocytic leukemia [4], splenic lymphoma [5] and nodal marginal zone lymphoma [6], which are quite distinct from the needl...
Source: Experimental Hematology - Category: Hematology Authors: Tags: Brief Communication Source Type: research
ConclusionThe use of a pediatric-inspired protocol for high-risk AYA ALL patients was effective and well tolerated with improvement in OS and DFS compared with historical data using adult protocols in such populations.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Leukemia | Lymphoma | Myeloma | Study